💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Infigratinib Phosphate

CHEMBL1834657 Phase 4 Approuvé Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
658.5 g/mol
LogP
—
Phase
4

This phosphate salt of infigratinib is the formulation used for the approved oral capsules for FGFR2-altered bile duct cancer. The phosphate salt improves the compound's stability and pharmaceutical properties. It blocks FGFR2 fusion proteins that abnormally activate cancer cell growth signaling.

Masse moléculaire

658,5000 g/mol

TPSA

173,00 Ų

Aires thérapeutiques

Bladder Cancer

Mécanisme d'action

Engineered protein combining domains from two different proteins to achieve enhanced therapeutic activity, often linking a receptor-binding domain with an immunoglobulin Fc region for extended half-life.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Engineered protein combining domains from two different proteins to achieve enhanced therapeutic activity, often linking a receptor-binding domain with an immunoglobulin Fc region for extended half-life.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1.O=P(O)(O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C26H31Cl2N7O3.H3O4P/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28;1-5(2,3)4/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31);(H3,1,2,3,4)

                

                

                

                    
                    

                        
Molecular Formula

                        
C26H34Cl2N7O7P

                    

                    
                    

                        
HBD / HBA

                        
5 / 12

                    

                    
                    

                        
Liaisons Rotatives

                        
8

                    

                    
                    
                    

                        
Atomes Lourds

                        
43

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
This phosphate salt of infigratinib is the formulation used for the approved oral capsules for FGFR2-altered bile duct cancer. The phosphate salt improves the compound's stability and pharmaceutical properties. It blocks FGFR2 fusion proteins that abnormally activate cancer cell growth signaling.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Engineered protein combining domains from two different proteins to achieve enhanced therapeutic activity, often linking a receptor-binding domain with an immunoglobulin Fc region for extended half-life.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Infigratinib Phosphate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1834657.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 56669626.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.